Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of Sepsis Response Team in the Emergency Department

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03789838
Recruitment Status : Completed
First Posted : December 31, 2018
Last Update Posted : December 31, 2018
Sponsor:
Information provided by (Responsible Party):
Aleksander Rygh Holten, Oslo University Hospital

Tracking Information
First Submitted Date December 27, 2018
First Posted Date December 31, 2018
Last Update Posted Date December 31, 2018
Actual Study Start Date May 15, 2017
Actual Primary Completion Date May 15, 2018   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: December 27, 2018)
Time from arrival the emergency department to antibiotic is given. [ Time Frame: 6 months ]
Time from arrival the emergency department to antibiotic is given.
Original Primary Outcome Measures Same as current
Change History No Changes Posted
Current Secondary Outcome Measures Not Provided
Original Secondary Outcome Measures Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title Effect of Sepsis Response Team in the Emergency Department
Official Title Prospective Cohort Study Examining the Effect of a Sepsis Rapid Response Team in the Emergency Department
Brief Summary Does sepsis response team in the emergency department increase the portion of sepsis patient who receive adequate treatment within one hour?
Detailed Description Does sepsis response team in the emergency department increase the portion of sepsis patient who receive adequate treatment within one hour? The time from the patients arrive at the emergency department to an adequate antibiotic is given, before and after introduction of a sepsis response team, was registered.
Study Type Observational [Patient Registry]
Study Design Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration 1 Year
Biospecimen Not Provided
Sampling Method Non-Probability Sample
Study Population Adult patients with suspected sepsis in emergency department
Condition Sepsis
Intervention Other: Sepsis rapid response team
Patients with suspected sepsis is managed by a sepsis rapid response team in a structured manner.
Study Groups/Cohorts
  • Before of sepsis rapid response team
    Time from arrival at the Emergency Department to antibiotic is administered, before introduction of sepsis response team in the Emergency Department.
  • Sepsis rapid response team
    Time from arrival at the Emergency Department to antibiotic is administered, with sepsis response team in the Emergency Department.
    Intervention: Other: Sepsis rapid response team
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Completed
Actual Enrollment
 (submitted: December 27, 2018)
245
Original Actual Enrollment Same as current
Actual Study Completion Date May 15, 2018
Actual Primary Completion Date May 15, 2018   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • Patients with suspected sepsis

Exclusion Criteria:

  • Patients who was consider not to need antibiotics
Sex/Gender
Sexes Eligible for Study: All
Ages 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Norway
Removed Location Countries  
 
Administrative Information
NCT Number NCT03789838
Other Study ID Numbers Ulleval sepsis-01
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement
Plan to Share IPD: No
Responsible Party Aleksander Rygh Holten, Oslo University Hospital
Study Sponsor Oslo University Hospital
Collaborators Not Provided
Investigators
Principal Investigator: Aleksander Holten, Phd, MD Oslo University Hospital
PRS Account Oslo University Hospital
Verification Date December 2018